Physician profile
Alejandra Campos
NPI 1932195146
$27,008.41
in general payments reported to CMS, 2019-2025
44 companies · $3,694 in 2025
The $3,694 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,724 · 2020: $3,034 · 2021: $4,666 · 2022: $3,878 · 2023: $3,427 · 2024: $3,586 · 2025: $3,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $53.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,654.01 |
| Education | $53.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,259.59 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $3,553.18 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $3,311.37 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $2,076.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $1,936.36 | 2019-2021 | |
| Amarin Pharma, INC. | $1,801.45 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,282.17 | 2019-2025 | Jardiance, Synjardy |
| Biohaven Pharmaceuticals, INC. | $1,268.96 | 2021 | |
| Antares Pharma, INC. | $1,003.16 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Amgen INC. | $693.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $661.26 | 2022-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $642.68 | 2019-2021 | |
| Mylan Specialty L.P. | $512.49 | 2022-2024 | Yupelri |
| Allergan, INC. | $511.43 | 2019-2020 | |
| Pfizer INC. | $494.74 | 2020-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandra Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.